Centene reimbursement benefits weighted to 2H14, says Susquehanna Susquehanna remains Positive on Centene following better than expected Q4 results citing the long term revenue growth opportunities presented by the new healthcare law coverage expansions. The firm noted the reimbursement benefits are weighted to the second half of 2014 and as such Q1 earnings could differ materially from their estimates. Price target is $68.
News For CNC From The Last 14 Days
Check below for free stories on CNC the last two weeks.